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INTRODUCTION    
Dissolution of drugs from solid dosage forms is a key 
parameter in assessing the product quality and uniformity 
at the formulation stage as well as throughout the shelf-
life of the product1. In case of lipophilic drugs 
dissolution rate can be the rate-limiting step in the in 
vivo absorption process and hence the dissolution 
medium is a critical component of the test that can cause 
problems2,3.Therefore, dissolution method should be 
discriminative, reproducible, scientifically justifiable and 
more importantly biorelevant4. This clinical relevance of 
dissolution testing can be achieved in the context of 
Quality by Design derived from a specific case study for 
a BCS 2 compound 5. 
 Approaches usually used in the design of a dissolution 
media for poorly water soluble drugs include: (6) 
1) Bringing about drug solubility by increasing the 
volume of the aqueous sink or removing the dissolved 
drug. 
2) Solubilization of drug by cosolvents up to 40% by 
addition of anionic or non-anionic surfactants to 
dissolution medium in post micellar concentration. 
3) Alteration of pH to enhance the solubility of insoluble 
drug molecule. 
Surfactant solutions are often proposed as dissolution 
media for drugs characterized by low water solubility. 
Generally, aqueous solutions of such surfactants may 
simulate the physiological environment more accurately 
rather than using adsorbents or hydroalcoholic and 
aliphatic media7. However, Tang and coworkers showed 
that for a low solubility drug, increase in solubility by 
addition of surfactants to meet sink conditions (based on 
bulk drug solubility data) may not always produce 
biorelevant results8. 
Aqueous buffers can be used to reflect typical pH 
conditions in the stomach or small intestine, but do not 
represent other key aspects of the composition of the GI 
contents (e.g., Osmolality, ionic strength, viscosity, 
surface tension) that can be relevant to drug release from 
the dosage form to be tested. In particular, they cannot be 
used to simulate the influence of food ingestion on drug 
release.  
Normal adult diet contains about 150gm of lipids, 95% 
of which are long-chain triglycerides and 4-8gm of 
phospholipids mainly composed of lecithin9. In fed state 
bioavailability of drug can be increased when there will 
be change in GIT environment such as 10 
1) Prolonged gastric emptying and decrease in intestinal 
motility increasing the time available for 
Solubilization. 
2) Increased dissolution rate and Solubilization of drug 
substances in mixed micells due to simulation of 
pancreatic secretion of bile salts and lipase. 
3) Protection from gastric/luminal degradation, due to 
protection in lipids. 
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4) Increased lymphatic transport, thus avoiding first pass 
metabolism. 
Specifically in the case of poorly soluble compounds, it 
is often observed that the in vivo fraction absorbed 
increases when the drug is given with a meal. Thus, in 
order to simulate the effects of food on dissolution in the 
GI tract, it is equally important to develop representative 
dissolution tests for both the fasted and fed states11. 
This article mainly focuses on composition of 
Biorelevant dissolution medium for poorly water soluble 
drug with the necessary steps that need to be considered 
for development of Biorelevant Dissolution Medium. 
Bio-relevant Dissolution Media 
Compendial dissolution media often fail to yield 
IVIVC’s for class 2 drugs because relevant physiological 
parameters are not taken into account. A suitable in vitro 
model should include a medium that mimics as much as 
possible the GIT contents after food intake 12, 13. 
Biorelevant in vitro dissolution testing is useful for 
qualitative forecasting of formulation and food effects on 
the dissolution and availability of orally administered 
drugs14, 15. These biorelevant media can be used to assess 
the performance of different formulations for poorly 
water soluble compounds. Biorelevant media have been 
successfully applied over the past decade to obtain 
IVIVCs16, 17, 18.Two bio-relevant dissolution media 
simulating conditions in the proximal small intestine 
FaSSIF and FeSSIF were proposed in 1998.  
Bio-relevant dissolution methods, combined with 
permeability measurements and computational 
simulations, were used to predict the oral absorption of 
drug 19. Due to their complex composition, these media 
are expensive and need to be prepared on the day of the 
experiment 20. 
Before the development of biorelevant dissolution 
medium the following steps should be considered  
1) Fluid composition in the GIT 
2) Hydrodynamics in the GIT 
3) API/formulation properties 
4) Prediction of plasma profile 
5) Development of IVIVCs  
1) Fluid composition of GIT 
The features of GI fluid are altered in fasted and fed 
condition and they affect the dissolution. Several 
physiochemical and physiological properties of GI fluids 
such as pH, buffer capacity, bile component 
concentration and state of aggregation and enzyme 
activity can greatly influence the drug dissolution 
process 21, 22, 23. For simulation of GI fluid the 
composition of GI fluid plays important role because 
upon simulating biological environment after a 
convenient alternative could facilitate routine and 
experimental in vitro dissolution work (24). Several 
physiologically based models for GI transit and 
absorption have been developed recently 25. 
Stomach: 
Motility in the stomach and small bowel is organized 
into two basic motor patterns fasting and fed. Fasting 
motor pattern is characterized by cyclic repetition of 
periods of quiescence altering with periods of contractile 
activity. Fed motor pattern is characterized by irregular 
but persistant phasic contractile activity. It develops 
almost immediately after ingestion of food and replaces 
the fasting pattern at whatever point in the interdigestive 
cycle the meal is eaten26. Under fasting condition pH of 
healthy human stomach is acidic, ranging between 1 and 
3. Fluid volume in the stomach would initially be around 
300ml in fasted state and 500ml or more in the fed state. 
The problem while carrying out the dissolution test in 
FeSSGF is that the medium contains milk, which cannot 
be filtered using filters with a pore size in the range of 
20-500 nm. 
Intestine: 
Motility of intestine comprises of intraluminal flow, 
motion of the wall that induce the flow and systems that 
regulate the wall motions 26. Fluid volume in small 
intestine is of 200ml in fasted state and 1L in the fed 
state 27. It has been found that the bioavailability of 
poorly soluble drug can be markedly enhanced by meal 
intake and its related changes in GI tract physiology such 
as secretions, digestion processes and motility 28. The 
human intestinal fluid contains bile salts, phospholipids, 
monoglycerides, free fatty acids and cholesterol. The 
increased solubility in FeSSIF-V2 can be explained by 
the formation of solubilizing micelles from bile salts, 
lecithin, GMO and sodium oleate29.  
Vertzoni et al have proposed that the surface tension 
could be lowered appropriately with combination of 
pepsin and very low concentration of bile salt. Bile salts 
and lecithin can increase the wetting process for the 
lipophilic drugs and solubilize the drug into the micelles 
formed by bile salts and lecithin. Composition of bile 
salts in human shown in table 130. 
Table 1: Composition of bile salts in human 
Conjugated bile acids Percentage  in 
bile salts 
Cholyglycine 24 
Chenglycine 24 
Deoxycholyglycine 16 
Cholyltaurine  12 
chenyltaurine 12 
deoxycholytaurine 8 
Sulfolithocholylglycine 3 
Sulfolithocholytaurine 1 
Lithocholyglycine 0.7 
Lithocholyltaurine 0.3 
 
Colon: 
Unlike the motility of the stomach and small intestine 
which is characterized by the cyclic appearance of the 
migrating motor complex under fasted conditions, 
colonic motility is rather limited and in progress due to 
its inaccessibility and regional differences in structure 
and function. 
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The composition of biorelevant media which are 
proposed by dissolution scientist in fasted and fed state 
for stomach, intestine and colon are shown in table from 
2-6 31. 
 
Table 2: Composition of the Media to Simulate Gastric Contents in the Fasted State 
Gastric Contents SGFSLS SGFTriton FaSSGF 
Sodium lauryl sulfate(%w/v) 0.25/0.05 - - 
Triton X 100 (%w/v) - 0.1 - 
Pepsin (mg/ml) - - 0.1 
NaTc ( µm) - - 80 
Lecithin (µm) - - 20 
NaCl 34.2 34.2 34.2 
pH 1.2 1.2 1.6 
Surface Tension (mN/m) 33.7 32.0 42.6 
Osmolality (mOsml/Kg) 180± 3.6 157.7± 2.9 120.7± 2.5 
 
Table 3: Composition of the Media to Simulate Gastric contents in the Fed State 
Gastric Contents Early Middle Late 
Sodium chloride (mM) 148 237.02 122.6 
Acetic acid (mM) - 17.12 - 
Sodium acetate( mM) - 29.75 - 
Ortho-phosphoric acid (mM) - - 5.5 
Sodium dihydrogen phosphate (mM) - - 32 
Milk: buffer 1:0 1:1 1:3 
Hydrochloric acid/sodium hydroxide qs pH 6.4 qs pH 5 qs pH 3 
pH 6.4 5 3 
Osmolality (mOsmol/Kg) 559± 10 400±10 300±10 
Buffer capacity (mml/pH) 21.33 25 25 
 
Table 4: Composition of the Media to Simulate the Contents of the Small Intestine in the Fasted State 
Contents of the Small Intestine FaSSIF FaSSIF-V2 
Sodium Taurocholate (mM) 3 3 
Lecithin (mM) 0.75 0.2 
Dibasic sodium phosphate (mM) 28.65 - 
Maleic acid (mM) - 19.12 
Sodium hydroxide (mM) 8.7 34.8 
Sodium chloride (mM) 105.85 68.62 
pH 6.5 6.5 
Osmolality (mOsmol/Kg) 270± 10 180± 10 
Buffer capacity (mmol/l/pH) 12 10 
 
Table 5:   Composition of the media to simulate the Contents of the Small Intestine in the Fed State 
Contents of the Small Intestine FeSSIF Early Middle Late FeSSIF-V2 
Sodium Taurocholate (mM) 15 10 7.5 4.5 10 
Lecithin (mM) 3.75 3 2 0.5 2 
Glyceryl monooleate (mM) - 6.5 5 1 5 
Sodium oleate (mM) - 40 30 0.8 0.8 
Acetic acid 140 - - - - 
Maleic acid - 28.6 44 58.09 55.02 
Sodium hydroxide (mM) 101 52.5 65.3 72 81.65 
Sodium chloride (mM) 173 145.2 122.8 51 125.5 
pH 5.0 6.5 5.8 5.4 5.8 
Osmolality (mOsmol/Kg) 635± 10 400± 10 390± 10 240± 10 390± 10 
Buffer capacity (mmol/L/pH) 76 25 25 15 25 
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Table 6: Composition of the Medium to Simulate the 
Colonic Fluid (SCoF) 
Composition SCoF 
Acetic acid (mM) 170 
NaOH (mM) 157 
pH 5.8 
Osmolality (mOsmol/Kg) 295 
Buffer capacity (mmol/l/pH) 29.1 
Ionic strength 0.16 
 
pH decreases with increase in temperature and decreases 
when the temperature is lowered to 240C. The pH 
changes at elevated temperature necessitated addition of 
different amounts of NaOH for maintaining the medium 
within the physiological range. This could in turn have 
an influence on osmolality changes 32. Osmolality is 
determined by freezing-point depression using an 
osmometer, buffer capacity is determined by titration 
with 1 M hydrochloric acid and surface tension is 
measured using stalagnomet33. The dissolved gases can 
cause changes in the performance of the dissolution 
medium by changing pH, forming bubbles on the dosage 
form or altering the interaction of the medium and the 
API. Extensive studies have been performed examining 
appropriate technique for the removal of dissolved gases 
from aqueous media which include a combination of 
heating and vaccum filtration followed by stirring under 
vaccum , vaccum filtration, heating, Sonication, helium 
sparing and membrane filtration34. For stability reason all 
media were used within 24 hrs after preparation.  
Taupitz et al suggested that these biorelevant media can 
be simplified by using SLS and Tween 80 to replace bile 
compounds 35. In some cases of  poorly water soluble 
drugs, existing media such as FaSSIF and FeSSIF were 
not enough to predict the absorption behavior of drug so 
that MREVID 1 and 2 was proposed as a new in-vitro 
dissolution medium to describe the in-vivo dissolution 
behavior 36. The composition of MERVID dissolution 
medium shown in Table 7.   
Table 7: Composition of medium reflecting in-vivo 
dissolution (MREVID) 
Composition MREVID 1 MREVID 2 
Sodium Taurocholate (mM) 30 22.5 
Phosphatidylcholine (mM) 7.5 5.625 
Buffer (g/L) 
KH2PO4 
KCL 
 
3.9 
7.7 
 
3.9 
7.7 
pH 6.5 6.5 
 
Diakidou et al performed simulation of gastric lipolysis 
and predicted the Felodipine release from a matrix tablet 
in the fed stomach and concluded that modeling 
intragastric lipolysis is necessary in order to simulate 
felodipine release from extended release tablet in fed 
stomach 37.  
2) Hydrodynamics: 
The dissolution fluid flow characteristics should consist 
of a predictable pattern that is free of irregularities or 
variable turbulence. Hydrodynamics is predominant for 
the overall dissolution rate if the mass transfer process is 
mainly controlled by convection/diffusion as is usually 
the case for poorly soluble substances. A thorough 
knowledge of hydrodynamics is useful in the course of 
dissolution method development and formulation 
development for pharmaceutical industries quality needs 
27. The dissolution apparatus used for different 
formulation are shown in Table 8. 
Table 8: Apparatus used for different formulation 
Types of dosage form Release method 
Solid oral dosage form Basket,paddle,reciprocating 
cylinder 
Implants Modified flow through cell 
Chewing gum                                                              Special apparatus
Powders & granules  Flow through cell 
 
Muscular contraction in the wall of the small intestine 
achieve two objectives one is stirring of the contents to 
increase exposure to enzymes and to bring the luminaly 
digested products close to the wall and second 
propulsion of indigestible material towards the distal gut. 
Abrahamsson demonstrated that human intestinal 
hydrodynamics were reflected in vitro using the paddle 
method at stirring rates of about 140rpm. However, 
human studies to establish such correlation are expensive 
and time consuming. He had used, Labradors as the 
anatomy and physiology of GI tract of Labradors 
resembles those of the human GI tract. This canine breed 
can serve as a model to simulate human intestinal 
hydrodynamics. The pharmacokinetic of felodipine 
matrix tablet (poorly soluble, neutral and lipophilic) in 
Labrador was studied. On the other hand micronized and 
coarse felodipine dissolution was carried out in 
biorelevant medium at various speeds (slower, medium, 
fast). In vitro AUC ratio of this particular experimental 
set up showed best agreement with the pharmacokinetic 
parameters 27. 
Cammarn et al have established a model for the 
dissolution of non-disintegrating salicylic acid tablets as 
a function of hydrodynamic conditions in the Flow 
Through Cell system (USP Apparatus 4). The approach 
was to model the dissolution rate of the material as a 
function of the Reynolds’s number 27. Reynolds number 
is commonly described as the ratio of momentum forces 
to viscous forces in a moving fluid 38.  
D’Arcy et al simulated hydrodynamics in the Levy 
beaker dissolution apparatus and explored the 
hydrodynamic characteristics of the apparatus. They also 
determined the hydrodynamics relevance to in vivo data 
used in IVIVCs through comparison of the magnitudes 
of velocities in the regions of the paddle, basket and 
Levy apparatuses where a dosage form would be located, 
with functions of in vitro dissolution rate data used in 
IVIVC studies39. 
Gao Zongming compared dissolution testing under finite 
and infinite sink conditions, this study applied both 
paddle and flow-through methods for dissolution testing 
with disintegrating prednisone and nondisintegrating 
salicylic acid tablets. The closed- and open-loop 
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configurations of the flow-through method were used to 
provide comparisons with the paddle method and the 
dissolution rates obtained using the two configurations 
were similar if the sink condition maintained 40.  
Mirza et al evaluated the dissolution Hydrodynamics in 
the USP, Peak™ and Flat-Bottom Vessels Using 
Different Solubility Drugs. The existence of the ‘dead 
zone‘at the bottom of the USP vessel was confirmed by 
performing perturbation (vessel tilt) studies using the 
USP Prednisone calibrator tablets, and two Novartis 
Development tablet formulations containing a low and a 
high solubility drug. All formulations formed a ‘cone‘of 
disintegrated mass at the bottom of the vessels. The 
hydrodynamic environment in the Peak™ and in flat-
bottom vessels was also evaluated using the low and high 
solubility drug formulations. There was no significant 
difference between the dissolution rates obtained by 
using the USP and flat-bottom vessels. The Peak vessel 
provided the highest release rates that were significantly 
different from those obtained by using USP and flat-
bottomed vessels. Finally, at higher paddle speeds of 60 
and 75 rpm, the results obtained from USP vessels were 
comparable to results from the Peak vessel operated at 50 
rpm 41. 
The NJIT group under Prof. Armenante studied the 
hydrodynamics of dissolution testing using Laser-
Doppler Velocimetry (LDV) and Computational Fluid 
Dynamics (CFD), respectively, to experimentally map 
and computationally predict the velocity distribution and 
the turbulent intensity inside a standard USP Apparatus 
II under the typical operating conditions mandated by the 
dissolution test procedure and concluded that the velocity 
in the region below the paddle is very low in magnitude 
42. 
3) API/Formulation characteristics 
Knowledge of the physiochemical nature of a compound 
in biorelevant media is useful for formulation 
development, which follows API phase selection. Based 
on this information the pKa profile of compound could 
be improved by modifying the surfactants or excipients 
in the formulation43. Many new chemical entities possess 
physiochemical characteristics unfavorable for oral 
absorption44.  
BCS: 
A biopharmaceutical classification system is a scientific 
framework for classifying the drug substance based on 
their aqueous solubility and intestinal permeability. The 
BCS was first devised in 1995, by Amidon et al and 
since then it has become a benchmark in the regulation 
of bioequivalence of oral drug products. According to 
BCS classification drugs can be categorized as follows 
Class 1: High solubility and high permeability 
Class 2: Low solubility and high permeability 
Class 3: High solubility and low permeability 
Class 4: Low solubility and low permeability 
For drugs belonging to class 1 and 3, simple aqueous 
media such as SGF and SIF (with or without enzymes) 
are suggested. In contrast for class 2 and 4 use of 
biorelevant media is recommended for dissolution 
testing. There are various methods of determination of 
solubility and permeability45. Galia et al 1998 showed 
use of biorelevant media to assess immediate release 
tablets. The study concludes that biorelevant media are 
preferable for BCS class 2 drugs, but do not improve the 
dissolution of BCS class 1 drugs.  
Solubility: 
Solubility is a crucial parameter for successful drug 
development as poor solubility compromises the 
Pharmacokinetic and Pharmacodynamic properties of 
drug (46). Solubility can be measured either 
thermodynamically or kinetically. Thermodynamic 
solubility can be defined as the concentration in solution 
of a compound in equilibrium with an excess of solid 
material at the end of the dissolution process and often 
considered as true solubility. Kinetic solubility considers 
the precipitation after dilution in a suitable solution of a 
compound predissolved in a co-solvent or in aqueous 
media by pH adjustment for ionizable compound 47. 
Solubility of drug in biorelevant dissolution media 
increased compared to the solubility in aqueous buffer 
because of enhanced wetting and micellar Solubilization 
48. Drug solubility testing in biorelevant media has 
become an indispensable tool in pharmaceutical 
development. Despite this importance, there is still an 
incomplete understanding of how poorly soluble 
compounds interact with these media. The study was 
carried out to apply the concept of the apparent 
solubilization capacity to fasted and fed state simulated 
intestinal fluid (FaSSIFand FeSSIF, respectively). A set 
of nonionized poorly soluble compounds was studied in 
biorelevant media prepared from an instantly dissolving 
complex at 37°C.The values of the solubilisation 
capacity were different between FaSSIFand FeSSIF but 
correlated. Drug inclusion into the mixed micelles was 
highly specific for a given compound. The ratio of the 
FeSSIF to FaSSIF solubility was in particular considered 
and discussed in terms of the apparent solubilizing 
capacity. The apparent Solubilization concept appears to 
be useful for the interpretation of biorelevant solubility 
tests. Further studies are needed to explore acidic and 
basic drugs 49, 50. 
Particle Size: 
The dissolution rate is directly proportional to the surface 
area of the drug. Reducing particle size leads to an 
increase in the surface area exposed to the dissolution 
medium, resulting in a greater dissolution rate. Thus, the 
dissolution rate of poorly soluble drugs can often be 
enhanced markedly by undergoing size reduction (e.g., 
through micronization). However, particle size reduction 
does not always improve the dissolution rate. This is in 
part attributed to adsorption of air on the surface of 
hydrophobic drugs, which inhibits the wetting and hence 
reduces the effective surface area. In addition, fine 
particles tend to agglomerate in order to minimize the 
surface energy, which also leads to a decrease in the 
effective surface area for dissolution. 
Drug pKa and gastrointestinal pH: 
51
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The amount of drug that exists in unionized form is a 
function of dissociation constant (pKa) of the drug and 
pH of the fluid at absorption sites. The relation between 
drug pKa and ionization and absorption is shown in 
Table 9. 
                       
Table 9: Relation between drug pKa and ionization 
Sr.No pKa range & drug nature pH/site of absorption 
1) Stronger acid(pKa< 2.5) Ionized at all pH values; Poorly absorbed from GIT. 
2) Moderately weak acid (pKa= 2.5-
7.5) 
Unionized in gastric pH values and ionized in intestinal; better 
absorbed from stomach. 
3) Very weak acid(pKa >8) Unionized at all pH values; absorbed along the entire length of GIT. 
4) Stronger base(pKa> 11) Ionized all pH values; Poorly absorbed from GIT. 
5) Moderately weak base(pKa= 5-11) Ionized at gastric pH; relatively unionized at intestinal pH; better 
absorbed from intestine. 
                                                                  
4) Prediction of plasma profile  
In vitro drug dissolution/release tests are conducted to 
estimate or predict in vivo drug release characteristics of 
a product. Direct estimation of in vivo drug dissolution is 
usually not possible and therefore blood drug 
concentration-time profiles are used for this purpose 52. 
The prediction of plasma profile can be done by using 
model dependent or model independent approaches. 
Wagner-Nelson, Loo-Riegelman and numerical 
deconvolution are such methods. Wagner-Nelson and 
Loo-Riegelman are both model dependent methods in 
which former is used for a one-compartment model and 
the latter for multi-compartment system 53. The 
prediction method using convolution analysis consists of 
following processes 54.  
1) The drug amount–time profile in each segment is 
calculated by the convolution method.  
2) The absorption rate–time profile in each segment is 
calculated by using the drug amount–time profile in 
each segment, calculated in step 1.  
3) The absorption rate–time profile in the whole GI tract 
is calculated as the sum of the absorption rate–time 
profiles of four segments obtained in step 2.  
4) Prediction of the plasma concentration–time curve of 
orally administered drug is performed by means of 
the convolution method.  
5) The total absorption rate– time data obtained in step 3 
and pharmacokinetic parameters after intravenous 
administration correspond to the input function and 
the weight function, respectively. The inverse 
Laplace transformation of the obtained equation by 
the convolution program gives the predicted plasma 
concentration profile after oral administration without 
the first-pass metabolism in intestinal epithelium 
and/or liver. 
 
The pharmacokinetic parameters determined by taking 
following consideration as study design, population 
study, study conditions, characteristics investigated 
during bioavailability study, bioanalytical methodology 
and  statistical evaluation 55. 
Rahman et al derived absorption profiles of Theophylline 
by using Wagner-Nelson equation. 
Fujioka et al tried to predict the in-vivo absorption 
kinetics of griseofulvin orally administered as a powder 
into rats, based on gastrointestinal transit absorption 
model (GITA), consisting of absorption, dissolution and 
GI- transit processes 56.    
5) Development of IVIVCs 
The term correlation is frequently employed within the 
pharmaceutical and related sciences to describe the 
relationship that exists between variables. 
Mathematically, the term correlation means 
interdependence between quantitative or qualitative data 
or relationship between measurable variables and ranks. 
From biopharmaceutical standpoint, correlation could be 
referred to as the relationship between appropriate in 
vitro release characteristics and in vivo bioavailability 
parameters. Two definitions of IVIVC have been 
proposed by the USP and by the FDA. 
United State Pharmacopoeia (USP) definition 
The establishment of a rational relationship between a 
biological property and a parameter derived from a 
biological property produced by a dosage form, and a 
physicochemical property or characteristic of the same 
dosage form. 
Food and Drug Administration (FDA) definition 
IVIVC is a predictive mathematical model that shows 
relationship between an in vitro property of a dosage 
form and a relevant in vivo response. Generally, the in 
vitro property is the rate or extent of drug dissolution or 
release while the in vivo response is the plasma drug 
concentration or amount of drug absorbed. 
OBJECTIVES OF IVIVC 
57, 58
 
IVIVC plays an important role in product development 
which serves as a surrogate of in vivo and assists in 
supporting biowaivers, supports and / or validates the use 
of dissolution methods and specifications and assists in 
quality control during manufacturing and selecting 
appropriate formulations. The different levels of IVIVC 
are listed in Table 1059, 60.   
To develop and validate an IVIVC model, two or three 
different formulations should be studied in vitro and in 
vivo (FDA guidance, 1997). Typically, the qualitative 
composition of drug products is the same, but the 
release-controlling variable(s), e.g., the amount of 
excipients, or a property of the drug substance such as 
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particle size, is varied. To develop a discriminative in 
vitro dissolution method, several method variables 
together with formulation variables are studied, e.g., 
different pH values, dissolution apparatuses and agitation 
speeds 61.
           
Table 10: Levels of IVIVCs 
 
Mainly two approaches are used for development of 
correlation  
 Two step 
Step 1: Estimate the in vivo absorption or dissolution 
time course using an appropriate technique for each 
formulation and subject 
Step 2: establish link model between in vivo and in vitro 
variables and predict plasma concentration from in vitro 
using the link model.  
 One step 
Predict plasma concentration from in vitro using a link 
model whose parameters are fitted in one step, so here it 
doesn’t involve deconvolution.  
The deconvolution technique requires the comparison of 
in vivo dissolution profile obtained from the blood 
profiles with in vitro dissolution profiles. It is the most 
commonly cited and used method in the literature. 
Perhaps that is the reason for the lack of success of 
developing IVIVC, since this approach is conceptually 
weak and difficult to use to derive the necessary 
parameters for their proper evaluation. For example: (1) 
Extracting in vivo dissolution data from a blood profile 
often requires elaborate mathematical and computing 
expertise. (2) It often requires multiple products having 
potentially different in vivo release characteristics (slow, 
medium, fast). These products are then used to define 
experimental conditions (medium, apparatus etc.) for an 
appropriate dissolution test to reflect their in vivo 
behaviour. (3) This technique requires blood data 
(human study) for the test products to relate it to in vitro 
results. 
An IVIVC should be evaluated to demonstrate that 
predictability of in vivo performance of a drug product 
from its in vitro dissolution characteristics is maintained 
over a range of in vitro dissolution release rates and 
manufacturing changes. Since the objective of 
developing an IVIVC is to establish a predictive 
mathematical model describing the relationship between 
an in vitro property and a relevant in vivo response, the 
proposed evaluation approaches focus on the estimation 
of predictive performance or, conversely, prediction 
error. Methodology for the evaluation of IVIVC 
predictability is an active area of investigation and a 
variety of methods are possible and potentially 
acceptable. A correlation should predict in vivo 
performance accurately and consistently. 
Internal predictability is applied to IVIVC established 
using formulations with three or more release rates for 
non-narrow therapeutic index drugs exhibiting 
conclusive prediction error 62.  
% PE = [(Observed parameter – Predicted parameter)/ 
(Predicted parameter)]*100 
According to the IVIVC guidance, the average prediction 
error across formulations cannot be greater than 10% and 
a formulation cannot have a prediction error greater than 
15%. Based on these criteria, each of the IVIVC models 
is valid in terms of the rate and extent of drug absorption 
63. 
External predictability evaluation is not necessary unless 
the drug is a narrow therapeutic index, or only two 
release rates were used to develop the IVIVC, or, if the 
internal predictability criteria are not met i.e. prediction 
error internally is inconclusive. However, since the 
IVIVC will potentially be used to predict the in vivo 
performance for future changes, it is of value to evaluate 
external predictability when additional data are available 
64. 
The prediction error for external validation should not 
exceed 10% where as % PE between 10 - 20% indicates 
inconclusive predictability and the need for further study 
using additional data sets. 
Various softwares have been developed such as Simcyp, 
GastroPlusTM, PK-SimTM, MEDICI-PKTM, Cloe PKTM 
etc. for physiological based pharmacokinetic model 
(PBPK)65, 66. 
The parameter such as metabolic factors, drug loss in 
GIT and stereochemistry are to be considered while 
developing IVIVC 67. 
Souliman et al. compared two in vitro models using a 
class I substance and found that the best IVIVC existed 
using an artificial digestive system. Thus, development 
of improved IVIVCs is possible using various models 
and fluids meant to simulate physiological conditions 68, 
69. 
 
Levels In vitro In vivo 
A Dissolution curve Absorption curve 
B Statistical moment MDT Statistical moments MRT,MAT etc. 
C Disintegration time, time to have 10, 50, 90 % 
dissolved, dissolution rate, dissolution efficiency 
Cmax, Tmax, Ka time to have 10, 50, 90 
% absorbed, AUC 
Multiple level C One or several pharmacokinetic parameters of 
interest 
Amount of drug dissolved at several time 
points 
D Not considered useful for regulatory purpose 
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CONCLUSION 
The development of Biorelevant dissolution medium 
mainly used as in vitro surrogate for in vivo 
performance. The compendial dissolution medium is 
unable to simulate the dissolution as that of in vivo so 
that the development of Biorelevant dissolution medium 
is necessary. During the development of Biorelevant 
medium the necessary steps should be consider which 
can be applied to assess drugs and their dosage forms 
during the course of drug product development. 
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ABBREVATIONS: 
API             Active Pharmaceutical Ingradient 
AUC           Area under curve 
BCS            Biopharmaceutical classification system 
CFD    Computational Fluid Dynamics  
FDA    Food and drug administration 
FeSSGF      Fed state simulated gastric fluid 
FeSSIF       Fed state simulated intestinal fluid 
FaSSIF       Fasted state simulated intestinal fluid 
GIT            Gastrointestinal tract 
GITA          Gastrointestinal transit absorption model 
GMO         Glycerylmonooleate 
IVIVC        In vitro in vivo correlation 
LDV    Laser-Doppler Velocimetry  
MERVID   Medium reflecting in-vivo dissolution 
NJIT          New jersey institute of technology 
USP           United state of pharmacopoeia
 
